Sangamo Therapeutics has signed a definitive licence agreement with Voyager Therapeutics for a therapy to treat prion disease, a neurodegenerative condition.
Sangamo has developed zinc finger transcriptional regulators (ZF-TRs) leveraging its epigenetic regulation platform. These ZF-TRs hinder the expression of the prion protein, which is the pathogenic driver of the disease.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sangamo has gained access to a capsid derived from the TRACER platform of Voyager.
Under a non-exclusive licence, Sangamo will merge a Voyager TRACER capsid with its ZF-TRs for treating the condition.
Sangamo will oversee the research, development, production and marketing of product candidates created using the Voyager capsid.
Voyager will receive specific licence payments and royalty payments on possible commercial sales of any products leveraging its capsid.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn the event that Sangamo out-licenses the prion programme, Voyager will receive a part of all licensing incomes linked to it.
Sangamo will file an investigational new drug application in 2025 for a product candidate for prion disease.
Sangamo CEO Sandy Macrae stated: “While evaluating delivery mechanisms for our zinc finger transcriptional regulators, we were pleased to identify Voyager’s capsid as being well suited to potentially achieve the specific central nervous system coverage required for this indication today.
“I’m excited to combine Sangamo’s cutting-edge epigenetic regulation capabilities with the delivery abilities of Voyager’s capsid to potentially create the first-ever meaningful therapy for prion disease.”
